	US 11,717,531 B2
	Preeclampsia
Meng Cai, Birmingham (GB); Keqinq Wang, Birmingham (GB); and Asif Ahmed, Birmingham (GB)
Assigned to MIRZYME THERAPEUTICS LIMITED, Birmingham (GB)
Filed by ASTON UNIVERSITY, Birmingham (GB)
Filed on Apr. 13, 2020, as Appl. No. 16/847,499.
Application 16/847,499 is a division of application No. 15/559,815, granted, now 10,617,708, previously published as PCT/GB2016/050710, filed on Mar. 16, 2016.
Claims priority of application No. 1504772 (GB), filed on Mar. 20, 2015.
Prior Publication US 2020/0289540 A1, Sep. 17, 2020
Int. Cl. A61K 31/713 (2006.01); C12N 15/11 (2006.01); C12Q 1/6883 (2018.01); G01N 33/50 (2006.01)

CPC A61K 31/713 (2013.01) [C12N 15/111 (2013.01); C12Q 1/6883 (2013.01); G01N 33/50 (2013.01); C12N 2310/113 (2013.01); C12N 2310/141 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/178 (2013.01)]

16 Claims

1. A method of increasing angiogenesis in a subject where angiogenesis is inhibited, comprising administering to a subject in need thereof an effective amount of at least one member of the group consisting of an inhibitor of microRNA-152 (miR-152), a functional fragment of the inhibitor of miR-152, and a combination thereof, wherein angiogenesis is increased in a subject with preeclampsia and/or Fetal Growth Restriction.